Company Announcement no. 34/2007
To: OMX Nordic Exchange Hørsholm, Denmark, December 27, 2007
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,
Section 28(a)
Hørsholm, Denmark, December 27, 2007; Pursuant to the Danish Securities Trading
Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily
basis, to make public transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and persons /
companies closely associated with these.
--------------------------------------------------------------------------------
| Name | Thomas Dyrberg |
--------------------------------------------------------------------------------
| Reason for reporting | Member of the Board of Directors |
--------------------------------------------------------------------------------
| Issuer and ID code/ISIN | LifeCycle Pharma A/S / DK0060048148 |
--------------------------------------------------------------------------------
| Type of transaction | Purchase of shares |
--------------------------------------------------------------------------------
| Date of transaction | December 21, 2007 |
--------------------------------------------------------------------------------
| Relevant market | OMX Nordic Exchange |
--------------------------------------------------------------------------------
| Number of traded securities | 5,000 |
--------------------------------------------------------------------------------
| Market value | DKK 181,000 |
--------------------------------------------------------------------------------
About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceuticals company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. Currently, the
Company has a diversified near- and medium-term pipeline, including a product
ready for US commercialization, five product candidates in clinical trials and
three in preclinical stages of development. LCP is listed on the OMX Nordic
Exchange under the trading symbol (OMX: LCP). For further information, please
visit www.lcpharma.com.
Contact:
LifeCycle Pharma A/S
Michael Wolff Jensen, EVP and CFO
+45 4074-6244; MWJ@lcpharma.com
or
Francesca M. DeMartino
Director, Investor Relations & Corporate Communications
(917) 747-4938; FDM@lcpharma.com
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)
| Source: Veloxis Pharmaceuticals A/S
Attachments
